USV Private Limited

USV Private Limited, established on August 25, 1961, is a prominent Indian pharmaceutical and biotechnology company headquartered in Mumbai, Maharashtra. Founded by Vithal Balkrishna Gandhi, the company has evolved into a leading producer of Metformin in India and operates across 75 countries globally.

The company is privately held, with authorized capital of ₹1,250 crore and paid-up capital of ₹915.91 crore. As of March 2026, USV Private Limited employs approximately 5,000 individuals. The company's official website is www.usvindia.com.

USV Private Limited operates seven manufacturing plants across India, including four dedicated to formulations, two for Active Pharmaceutical Ingredients (APIs), and one for biological drugs. These facilities adhere to current Good Manufacturing Practice (cGMP) standards, ensuring the production of high-quality pharmaceutical products. The company's manufacturing capabilities encompass oral solids, injectables (pre-filled syringes and vials), ophthalmics, biosimilars, and peptides.

The leadership team at USV Private Limited includes:

• Leena Tewari: Chairperson
• Prashant Tewari: Managing Director
• Jayant Dwivedy: Chief Operating Officer and Executive Director
• Deepak Keshav Ghaisas: Director
• Murugappan Muthiah Venkatachalam: Director
• Vilas Gandhi Tewari: Director
• Debabrata Bhadury: Director
• Aneesha Gandhi Tewari: Director

This team drives the company's strategic direction and operational excellence.

USV Private Limited has a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained over 100 product approvals worldwide and filed more than 30 Drug Master Files (DMFs) globally. This extensive regulatory compliance underscores USV's commitment to meeting international standards and facilitating market access in these regions.

In emerging markets across Africa, Latin America, and Southeast Asia, USV Private Limited leverages its World Health Organization (WHO) prequalification to enhance access to essential medicines. This strategic approach enables the company to expand its footprint and address healthcare needs in these regions effectively.

USV Private Limited's geographic strategy demonstrates a balanced diversification across various therapeutic categories and global markets. The company's export portfolio spans five therapeutic areas, with a concentration in diabetes and endocrine disorders, antibiotics, and Ayurvedic and herbal products. This diversification mitigates concentration risk and positions USV to capitalize on growth opportunities across different regions and therapeutic segments.

USV Private Limited maintains active registrations with the U.S. Food and Drug Administration (FDA) for its manufacturing facilities. The company has received approvals for Abbreviated New Drug Applications (ANDAs) and has filed multiple Drug Master Files (DMFs), reflecting its commitment to meeting FDA standards. Inspection histories indicate compliance with FDA regulations, further affirming the company's dedication to quality and safety in its products.

The company's manufacturing facilities are certified by the World Health Organization (WHO) and hold European Union Good Manufacturing Practice (EU GMP) certificates. These certifications validate USV Private Limited's adherence to international quality standards, ensuring the safety and efficacy of its pharmaceutical products in global markets.

USV Private Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained approvals from state drug controllers across India. The company also possesses export No Objection Certificates (NOCs), facilitating its international trade and compliance with Indian regulatory requirements.

As of March 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to USV Private Limited by regulatory authorities. This absence suggests a strong compliance record and adherence to regulatory standards.

In the pharmaceutical industry, USV Private Limited faces competition from both domestic and international companies. Key competitors include multinational corporations and other Indian pharmaceutical firms operating in similar therapeutic segments. Market share comparisons indicate that USV holds a significant position in the Indian market, particularly in the oral anti-diabetic and cardiac segments. The company's focus on quality, regulatory compliance, and diverse product offerings contributes to its competitive edge.

USV Private Limited's key differentiators include its strong presence in the diabetes and cardiology segments, extensive regulatory approvals across multiple countries, and a diversified product portfolio encompassing oral solids, injectables, ophthalmics, biosimilars, and peptides. These strengths enable the company to meet a wide range of patient needs and maintain a competitive position in the global pharmaceutical market.

USV Private Limited's current strategic direction focuses on expanding its generics and specialty products portfolio, with an emphasis on biosimilars and contract development and manufacturing organization (CDMO) services. The company's future outlook includes leveraging its R&D capabilities and global manufacturing footprint to drive growth and innovation in the pharmaceutical industry.

USV Private Limited has a robust track record in pharmaceutical manufacturing, with consistent export volumes and a diverse product range. The company's adherence to international quality standards, as evidenced by its certifications and regulatory approvals, underscores its reliability as a supplier. Ongoing monitoring of regulatory compliance and market performance is recommended to ensure sustained reliability.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm active registrations and approved ANDAs through the FDA's official database.
• WHO-GMP Certification: Obtain copies of WHO-GMP certificates from USV Private Limited.
• EU GMP Certification: Request EU GMP certificates from the company.
• ISO Certification: Verify ISO certifications related to quality management systems.

These certifications can be verified through the respective regulatory bodies' official channels or by requesting documentation directly from USV Private Limited.

Importers should undertake the following steps to ensure due diligence:

• Verify Regulatory Approvals: Confirm FDA registrations, WHO-GMP, and EU GMP certifications.
• Assess Financial Stability: Review the company's financial statements and credit history.
• Evaluate Manufacturing Capabilities: Inspect manufacturing facilities for compliance with quality standards.
• Check Compliance Records: Review any past regulatory actions or compliance issues.
• Assess Supply Chain Reliability: Evaluate the company's logistics and delivery performance.

Red flags to watch for include discrepancies in certification documents, unresolved regulatory issues, and inconsistent financial records. Recommended pre-order checks involve obtaining and verifying all relevant certifications, conducting site visits to manufacturing facilities, and consulting with regulatory bodies for the latest compliance information.